SANOFI PASTEUR

01 April 2020

Dear Healthcare Professional

Supply of Typhim Vi under labelling exemption

Sanofi is currently faced with supply shortage of Typhim Vi *(Salmonella typhi* vi polysaccharide vaccine) packaged in the Medsafe approved labelling. To address this issue, Sanofi has imported additional doses of Typhim Vi packaged using the Standard International syringe label that does not comply with New Zealand labelling requirements. It is important to note that the product, carton and package leaflet are identical to those currently supplied, including in terms of strength and volume (25 µg/mL *Salmonella typhi* vi polysaccharide in 0.5 mL). The differences only pertain to the syringe labelling and we are writing to you to ensure that you are aware of these differences.

The Standard International labelling is intended for the global market and hence is different to the labelling used in New Zealand.

New Zealand labelling **Typhim Vi 0.5 mL** **English**	**Standard International labelling** **Typhim Vi 0.5 mL** **French, English and Spanish**
Syringe Label	**Syringe Label**
	

sanofi-aventis australia pty ltd trading as SANOFI PASTEUR ABN 31 008 558 807
Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113 -
Tel: +61 (0) 2 8666 2000 – Fax: +61 (0) 2 8666 2201 - www.sanofi.com.au

In particular, the syringe label states that Typhim is approved for intramuscular (IM) or subcutaneous (SC) route (as is the case in some international markets). You should note that in New Zealand, Typhim Vi is approved for IM injection only. Consequently, the Typhim batch should not be used for SC administration in accordance with information currently registered in New Zealand.

Should you have any questions relating to this product, please call Sanofi Pasteur Medical Information at 0800 283 684.

Thank you for your understanding.

Regards,

Dr. Christian T. Felter, MD
Head of Medical, Sanofi Pasteur Australia and New Zealand